Publications

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

The Immune Landscape of Cancer

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identi...

Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Hepatocellular carcinoma

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic ag...

Pembrolizumab versus Ipilimumab in Advanced Melanoma

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

Comprehensive molecular profiling of lung adenocarcinoma

Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA ...

Versatile and open software for comparing large genomes

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Integrated genomic characterization of endometrial carcinoma

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

International audience